17159-80-7

Basic information

• Product Name: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE
• Synonyms: Ethyl 4-hydroxycyclohexanecarboxylate, mixture of cis and trans ,98%;ethyl 4-hydroxycyclohexane-1-carboxylate;Ethyl 4-hydroxycyclohexylcarboxylate;Ethyl 4-hydroxycyclohexanecarboxylate, Mixture of cis and trans 98%;Ethyl 4-hydroxycyclohexanecarbonate;Ethyl 4-hydroxycyclohexanecarboxylate≥ 99% (assay);ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE;Ethyl 4-hydroxycyclohexanecarboxylate,mixture of cis and trans
• CAS NO: 17159-80-7
• Molecular Formula: C₉H₁₆O₃
• Molecular Weight: 172.22
• EINECS: 241-215-1
• Product Categories: C8 to C9;Carbonyl Compounds;Esters
• Mol File: 17159-80-7.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 127-134 °C0.1 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.068 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00322mmHg at 25°C
• Refractive Index: n20/D 1.466(lit.)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 14.98±0.40(Predicted)
• Water Solubility: Not miscible or difficult to mix in water.
• CAS DataBase Reference: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE(17159-80-7)
• EPA Substance Registry System: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE(17159-80-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 17159-80-7(Hazardous Substances Data)

Usage

Uses

Ethyl 4-hydroxycyclohexanecarboxylate, cis + trans is used in the synthesis of other chemicals and as pharmaceutical intermediate.

Synthesis Reference(s)

The Journal of Organic Chemistry, 30, p. 4145, 1965 DOI: 10.1021/jo01023a039

InChI:InChI=1/C9H16O3/c1-2-12-9(11)7-3-5-8(10)6-4-7/h7-8,10H,2-6H2,1H3

Upstream product

• 123-91-1 1,4-dioxane 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 99-96-7 4-hydroxy-benzoic acid 
• 64-17-5 ethanol 
• 3685-26-5 trans-4-hydroxycyclohexanecarboxylic acid 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 

Downstream Products

• 17419-82-8 cis/trans-4-hydroxy-cyclohexanecarboxylic acid hydrazide 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 158009-09-7 4-(tert-butyl-dimethyl-silyloxy)cyclohexanecarboxylic acid ethyl ester 
• 7472-30-2 (4-chloro-cyclohexyl)-phenyl ketone 
• 36296-67-0 phenyl-(trans-4-phenyl-cyclohexyl)-ketone 
• 77528-71-3 2-Methyl-6-tosyloxymethyl-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 77528-76-8 6-Tosyloxymethyl-4,5,6,7-tetrahydro-benzo[d]thiazole 
• 39086-05-0 ethyl 3-bromo-4-oxocyclohexanecarboxylate 
• 116941-20-9 Acetic acid 4-cyano-cyclohexyl ester 
• 19556-98-0 cis-4-Acetoxy-cyclohexan-carbonsaeureamid 
• 19557-00-7 trans-4-Acetoxy-cyclohexan-carbonsaeureamid 
• 77407-27-3 trans-4-Cyanocyclohexanol 
• 147151-51-7 1-<(Tosyloxy)methyl>-4-methylenecyclohexane 
• 1415573-45-3 cis-ethyl 4-(pyridin-4-yloxy)cyclohexanecarboxylate 

Relevant articles and documents

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

IMIDAZOLE DERIVATIVES

Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.